the alias2002: like your reasoning, but doubt the CEO would cloak a near-term FDA approval prospect in such verbiage. The results of this trial are, in a word, underwhelming, and hardly the usual scenario for FDA approval, but as you and others here say, there is always that remote possibility. I personally am not doubling up on that chance.
Market Data 
Markets 
AI
